Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Flamen

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Clinical Nuclear Medicine|June 24, 2024
177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN StudyMagdalena Mileva, Camille Van Bogaert, Gwennaëlle Marin, et al.
Neuro-Oncology Advances|August 30, 2024
Results from a phase I study of 4-<i>l</i>-[131I]iodo-phenylalanine ([<sup>131</sup>I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1)Josef Pichler, Tatjana Traub-Weidinger, Kurt Spiegl, et al.
BMC Cancer|June 3, 2014
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN studyAmelie Deleporte, Marianne Paesmans, Camilo Garcia, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximabKristoff Muylle, Patrick Flamen, Danielle J Vugts, et al.
BJU International|December 17, 2016
Clinical impact of <sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approachSimone Albisinni, Carlos Artigas, Fouad Aoun, et al.
Oncotarget|February 29, 2020
Prognostic value of a three-scale grading system based on combining molecular imaging with <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasiasIoannis Karfis, Gwennaëlle Marin, Hugo Levillain, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 14, 2016
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancerErwin Woff, Alain Hendlisz, Camilo Garcia, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|March 1, 2018
Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot studyMégane Lemaire, Valerio Lucidi, Fikri Bouazza, et al.
Journal of Surgical Oncology|November 14, 2019
The metabolic clinical risk score as a new prognostic model for surgical decision-making in patients with colorectal liver metastasesIvan Duran Derijckere, Hugo Levillain, Ali Bohlok, et al.
Journal of Surgical Oncology|March 22, 2021
Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastasesAli Bohlok, Ivan Duran Derijckere, Hugues Azema, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Clinical Nuclear Medicine|June 24, 2024
177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN StudyMagdalena Mileva, Camille Van Bogaert, Gwennaëlle Marin, et al.
Neuro-Oncology Advances|August 30, 2024
Results from a phase I study of 4-<i>l</i>-[131I]iodo-phenylalanine ([<sup>131</sup>I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1)Josef Pichler, Tatjana Traub-Weidinger, Kurt Spiegl, et al.
BMC Cancer|June 3, 2014
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN studyAmelie Deleporte, Marianne Paesmans, Camilo Garcia, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximabKristoff Muylle, Patrick Flamen, Danielle J Vugts, et al.
BJU International|December 17, 2016
Clinical impact of <sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approachSimone Albisinni, Carlos Artigas, Fouad Aoun, et al.
Oncotarget|February 29, 2020
Prognostic value of a three-scale grading system based on combining molecular imaging with <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasiasIoannis Karfis, Gwennaëlle Marin, Hugo Levillain, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 14, 2016
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancerErwin Woff, Alain Hendlisz, Camilo Garcia, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|March 1, 2018
Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot studyMégane Lemaire, Valerio Lucidi, Fikri Bouazza, et al.
Journal of Surgical Oncology|November 14, 2019
The metabolic clinical risk score as a new prognostic model for surgical decision-making in patients with colorectal liver metastasesIvan Duran Derijckere, Hugo Levillain, Ali Bohlok, et al.
Journal of Surgical Oncology|March 22, 2021
Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastasesAli Bohlok, Ivan Duran Derijckere, Hugues Azema, et al.
Pageof 13